TYLENOL®: A Difference Worth Discussing
Effective for a wide range of patients, including those:
- on aspirin heart therapy1
- with a risk of GI irritation4
- with kidney dysfunction8,9
Scientific animation shows how the Mechanisms of Action (MOAs) of acetaminophen and
NSAIDs can have important implications for patient care. Introduction by pain specialist
Bruce D. Nicholson, MD.
REFERENCES 1. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Organ-specific warnings: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use—small entity compliance guide. July 2010. 3. Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications. Ther Clin Risk Manag. 2009;5(1):65-73. 4. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 5. American College of Cardiology. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118(18):1894-1909. 6. Bugge JF. Renal effects and complications of NSAIDs for routine post-operative pain relief: increased awareness of a real problem is needed. Bailliere’s Clinical Anesthesiology. 1995;9(3):483-492. 7. DeMaria AN, Weir MR. Coxibs—beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage. 2003;25(2S):S41-S49. 8. Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol. 1989;36(3):291-297. 9. Martin U, Temple RM, Winney RJ, Prescott LF. The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol. 1991;41(1):43-46.
Featured quotes are for illustrative purposes only and are not direct statements from actual patients.